X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8646) 8646
Book Review (1140) 1140
Publication (501) 501
Newsletter (248) 248
Conference Proceeding (59) 59
Magazine Article (58) 58
Newspaper Article (39) 39
Dissertation (38) 38
Book Chapter (27) 27
Trade Publication Article (8) 8
Web Resource (4) 4
Data Set (1) 1
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6361) 6361
alendronate (6115) 6115
humans (5351) 5351
female (4366) 4366
osteoporosis (4325) 4325
aged (2488) 2488
middle aged (2458) 2458
male (2210) 2210
bisphosphonates (2137) 2137
endocrinology & metabolism (2105) 2105
alendronate - therapeutic use (1777) 1777
bone density conservation agents - therapeutic use (1709) 1709
animals (1632) 1632
postmenopausal women (1623) 1623
bone density - drug effects (1551) 1551
fractures (1476) 1476
osteoporosis - drug therapy (1471) 1471
osteoporosis, postmenopausal - drug therapy (1385) 1385
women (1382) 1382
orthopedics (1366) 1366
bone density (1213) 1213
diphosphonates - therapeutic use (1172) 1172
postmenopausal osteoporosis (1119) 1119
bone-mineral density (1097) 1097
aged, 80 and over (1088) 1088
risk (1059) 1059
risk factors (1050) 1050
bones (973) 973
drug therapy (945) 945
bone density conservation agents - adverse effects (934) 934
bone density conservation agents - administration & dosage (929) 929
alendronate - administration & dosage (909) 909
bisphosphonate (907) 907
rats (900) 900
therapy (894) 894
abridged index medicus (869) 869
risedronate (864) 864
rheumatology (853) 853
alendronate - pharmacology (850) 850
medicine & public health (850) 850
medicine, general & internal (849) 849
treatment outcome (846) 846
adult (840) 840
prevention (826) 826
density (801) 801
alendronate - adverse effects (777) 777
bone mineral density (762) 762
vertebral fractures (759) 759
zoledronic acid (744) 744
bone (739) 739
diphosphonates - administration & dosage (714) 714
diphosphonates - adverse effects (705) 705
health aspects (691) 691
pharmacology & pharmacy (687) 687
research (680) 680
care and treatment (665) 665
bone density conservation agents - pharmacology (631) 631
analysis (599) 599
endocrinology (578) 578
mineral density (563) 563
diphosphonates - pharmacology (551) 551
time factors (551) 551
fractures, bone - prevention & control (528) 528
in-vitro (510) 510
diphosphonates (502) 502
dentistry (501) 501
etidronic acid - analogs & derivatives (497) 497
hip fracture (495) 495
surgery (490) 490
fracture (486) 486
bone remodeling - drug effects (484) 484
randomized-trial (478) 478
administration, oral (472) 472
mice (455) 455
double-blind method (446) 446
drug administration schedule (446) 446
risedronate sodium (445) 445
absorptiometry, photon (435) 435
bone and bones - drug effects (425) 425
dentistry, oral surgery & medicine (422) 422
dosage and administration (416) 416
phosphonates (415) 415
retrospective studies (407) 407
denosumab (398) 398
turnover (395) 395
teriparatide (394) 394
pamidronate (393) 393
resorption (385) 385
dose-response relationship, drug (384) 384
double-blind (383) 383
etidronic acid - therapeutic use (383) 383
medicine, research & experimental (377) 377
radiography (376) 376
osteoporosis - complications (374) 374
follow-up studies (371) 371
parathyroid-hormone (371) 371
trial (371) 371
biochemical markers (363) 363
hormone replacement therapy (363) 363
osteoporosis - prevention & control (354) 354
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8329) 8329
German (156) 156
Spanish (107) 107
Japanese (88) 88
French (68) 68
Portuguese (65) 65
Korean (51) 51
Chinese (47) 47
Turkish (31) 31
Italian (24) 24
Russian (23) 23
Norwegian (19) 19
Polish (17) 17
Danish (10) 10
Czech (6) 6
Slovak (6) 6
Croatian (5) 5
Dutch (5) 5
Hungarian (4) 4
Swedish (4) 4
Finnish (2) 2
Persian (2) 2
Serbian (2) 2
Slovenian (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 08/2019, Volume 144, Issue 2, p. 416
for the AsthmaNet Investigators Loss of bronchoprotection (LOBP) with a regularly used long-acting [beta].sub.2-adrenergic receptor agonist (LABA) is well... 
Alendronate
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 12, pp. 1189 - 1199
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 15, pp. 1417 - 1427
Among postmenopausal women with osteoporosis and a high risk of fracture, treatment with the monoclonal antibody romosozumab for 12 months followed by... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | BONE-MINERAL DENSITY | VERTEBRAL FRACTURES | DISEASE | AORTA | RANDOMIZED-TRIAL | RISK | STRENGTH | POSTMENOPAUSAL WOMEN | SCLEROSTEOSIS | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | Index Medicus | Abridged Index Medicus | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk | General & Internal Medicine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 20, pp. 2028 - 2039
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 01/2010, Volume 25, Issue 1, pp. 72 - 81
Journal Article
Osteoporosis International, ISSN 0937-941X, 1/2012, Volume 23, Issue 1, pp. 305 - 315
Strontium ranelate appears to influence more than alendronate distal tibia bone microstructure as assessed by high-resolution peripheral quantitative computed... 
Osteoporosis | Medicine & Public Health | Alendronate | Orthopedics | Gynecology | Rheumatology | Finite elements analysis | Strontium ranelate | HR-pQCT | Microstructure | Endocrinology | HRpQCT | CORTICAL BONE | ELASTIC PROPERTIES | STRENGTH | QUANTITATIVE COMPUTED-TOMOGRAPHY | TRABECULAR BONE | VERTEBRAL FRACTURES | DISTAL RADIUS | ENDOCRINOLOGY & METABOLISM | ARCHITECTURE | PARATHYROID-HORMONE | POSTMENOPAUSAL WOMEN | Bone and Bones - pathology | Thiophenes - therapeutic use | Radius - pathology | Humans | Middle Aged | Osteoporosis, Postmenopausal - pathology | Tomography, X-Ray Computed | Tibia - pathology | Alendronate - therapeutic use | Bone and Bones - drug effects | Bone and Bones - diagnostic imaging | Osteoporosis, Postmenopausal - diagnostic imaging | Radius - drug effects | Organometallic Compounds - therapeutic use | Female | Finite Element Analysis | Lumbar Vertebrae - physiopathology | Double-Blind Method | Tibia - diagnostic imaging | Bone Density Conservation Agents - therapeutic use | Thiophenes - pharmacology | Tibia - drug effects | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Alendronate - pharmacology | Femur Neck - physiopathology | Osteoporosis, Postmenopausal - physiopathology | Aged | Organometallic Compounds - pharmacology | Radius - diagnostic imaging | Structure | Bones | Analysis | Index Medicus | Dual energy X-ray absorptiometry | Radius | Transformation | Bone turnover | Bisphosphonates | Stress | Post-menopause | Strontium | Alendronic acid | Fractures | Computed tomography | Tibia | Risk assessment | Bone mineral density | Bone strength | Age
Journal Article
02/2013
Background: Osteoporosis is a chronic disease characterized by a decrease in bone mineral density (BMD) and corruption of the microarchitectural structure of... 
Osteoporosis | Methylprednisolon | Alendronate | Ovariectomy | Metyrosine
Web Resource
Biomaterials, ISSN 0142-9612, 2013, Volume 34, Issue 15, pp. 3795 - 3806
Abstract Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases. Growing evidence suggests that... 
Advanced Basic Science | Dentistry | Angiogenesis | Dendrimers | PEG | Bone targeting | Alendronate | Polymer therapeutics | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | PACLITAXEL | MACROMOLECULAR THERAPEUTICS | BISPHOSPHONATES | ANTICANCER | HIGH-RISK | PROSTATE-CANCER | AGENTS | DRUG-DELIVERY SYSTEMS | Neovascularization, Physiologic - drug effects | Paclitaxel - pharmacology | Human Umbilical Vein Endothelial Cells - metabolism | Apoptosis - drug effects | Humans | Bone Neoplasms - secondary | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Tibia - pathology | Alendronate - chemistry | Alendronate - therapeutic use | Paclitaxel - chemistry | Human Umbilical Vein Endothelial Cells - cytology | Micelles | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Bone Neoplasms - drug therapy | Alendronate - pharmacokinetics | Tissue Distribution - drug effects | Human Umbilical Vein Endothelial Cells - drug effects | Treatment Outcome | Antineoplastic Agents - chemistry | Tibia - drug effects | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Xenograft Model Antitumor Assays | Animals | Fluorescein-5-isothiocyanate | Breast Neoplasms - pathology | Alendronate - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Ethylene glycol | Care and treatment | Phosphonates | Paclitaxel | Aluminum compounds | Fluorescence | Breast cancer | Metastasis | Drug therapy | Cancer | Index Medicus | Drugs | Imaging | Breast | Bones | Conjugation | Tumors
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 08/2010, Volume 25, Issue 8, pp. 1886 - 1894
Journal Article
Clinical calcium, ISSN 0917-5857, 2009, Volume 19, Issue 7, pp. 970 - 975
Journal Article
Journal Article
Osteoporosis International, ISSN 0937-941X, 1/2012, Volume 23, Issue 1, pp. 317 - 326
The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent... 
Adherence | Persistence | Medicine & Public Health | Alendronate | Compliance | Orthopedics | Gynecology | Rheumatology | Denosumab | Endocrinology | MEDICATION | FRACTURE RATES | OSTEOPOROSIS | LOW BONE MASS | THERAPY | INJECTION | PATIENT PREFERENCE | ENDOCRINOLOGY & METABOLISM | BELIEFS | QUESTIONNAIRE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Alendronate - therapeutic use | Antibodies, Monoclonal, Humanized | Injections, Subcutaneous | Female | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Administration, Oral | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Patient Preference | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Cross-Over Studies | Alendronate - adverse effects | Bone Density - drug effects | Medication Adherence | RANK Ligand - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Osteoporosis, Postmenopausal - physiopathology | Aged | Alendronate - administration & dosage | Patient compliance | Research | Clinical trials | Comparative studies | Drug therapy | Womens health | Index Medicus | Alendronic acid | Osteoporosis | Bone mineral density | Tablets | Bisphosphonates | Post-menopause | Original
Journal Article